Abstract

BackgroundUtilization of RNA sequencing methods to measure gene expression from archival formalin-fixed paraffin-embedded (FFPE) tumor samples in translational research and clinical trials requires reliable interpretation of the impact of pre-analytical variables on the data obtained, particularly the methods used to preserve samples and to purify RNA.MethodsMatched tissue samples from 12 breast cancers were fresh frozen (FF) and preserved in RNAlater or fixed in formalin and processed as FFPE tissue. Total RNA was extracted and purified from FF samples using the Qiagen RNeasy kit, and in duplicate from FFPE tissue sections using three different kits (Norgen, Qiagen and Roche). All RNA samples underwent whole transcriptome RNA sequencing (wtRNAseq) and targeted RNA sequencing for 31 transcripts included in a signature of sensitivity to endocrine therapy. We assessed the effect of RNA extraction kit on the reliability of gene expression levels using linear mixed-effects model analysis, concordance correlation coefficient (CCC) and differential analysis. All protein-coding genes in the wtRNAseq and three gene expression signatures for breast cancer were assessed for concordance.ResultsDespite variable quality of the RNA extracted from FFPE samples by different kits, all had similar concordance of overall gene expression from wtRNAseq between matched FF and FFPE samples (median CCC 0.63–0.66) and between technical replicates (median expression difference 0.13–0.22). More than half of genes were differentially expressed between FF and FFPE, but with low fold change (median |LFC| 0.31–0.34). Two out of three breast cancer signatures studied were highly robust in all samples using any kit, whereas the third signature was similarly discordant irrespective of the kit used. The targeted RNAseq assay was concordant between FFPE and FF samples using any of the kits (CCC 0.91–0.96).ConclusionsThe selection of kit to purify RNA from FFPE did not influence the overall quality of results from wtRNAseq, thus variable reproducibility of gene signatures probably relates to the reliability of individual gene selected and possibly to the algorithm. Targeted RNAseq showed promising performance for clinical deployment of quantitative assays in breast cancer from FFPE samples, although numerical scores were not identical to those from wtRNAseq and would require calibration.

Highlights

  • Utilization of RNA sequencing methods to measure gene expression from archival formalin-fixed paraffin-embedded (FFPE) tumor samples in translational research and clinical trials requires reliable interpretation of the impact of pre-analytical variables on the data obtained, the methods used to preserve samples and to purify RNA

  • Expression from whole transcriptome RNA sequencing (RNAseq) and microarrays prepared from 57 fresh frozen (FF) breast cancers demonstrated strong correlation (r > 0.9) for many genes, including Estrogen receptor (ESR1), Progesterone receptor (PGR) and Human epidermal growth factor 2 receptor (ERBB2) (HER2 receptor), and established multigene signatures such as EndoPredict and OncotypeDX (r > 0.95) [3]

  • We evaluated which wtRNAseq library preparation protocols provide the best calibration between FFPE and FF samples

Read more

Summary

Introduction

Utilization of RNA sequencing methods to measure gene expression from archival formalin-fixed paraffin-embedded (FFPE) tumor samples in translational research and clinical trials requires reliable interpretation of the impact of pre-analytical variables on the data obtained, the methods used to preserve samples and to purify RNA. Expression from whole transcriptome RNAseq (wtRNAseq) and microarrays prepared from 57 fresh frozen (FF) breast cancers demonstrated strong correlation (r > 0.9) for many genes, including ESR1 (estrogen receptor), PGR (progesterone receptor) and ERBB2 (HER2 receptor), and established multigene signatures such as EndoPredict and OncotypeDX (r > 0.95) [3]. Based on such promising analytical performance, attention should be given to development of evidence-based standard operating procedures for clinical-level implementation with routine formalinfixed paraffin-embedded (FFPE) tumor samples, for both targeted and wtRNAseq applications. We identified the RNase H-based KAPA kit for rRNA depletion and sequencing library preparation as our preferred FFPE library preparation protocol for subsequent projects [12]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.